BofA Finance LLC has filed a pricing supplement for $1 million in Contingent Income Issuer Callable Yield Notes, which are set to be issued on October 30, 2026. This offering is fully and unconditionally guaranteed by Bank of America Corporation. The notes are linked to the performance of the EURO STOXX 50 Index, the Russell 2000 Index, and the SPDR Gold Shares. This move indicates BofA Finance's strategy to diversify its offerings in the competitive national commercial banking sector.
Background
BofA Finance LLC operates under the SIC code 6021, which corresponds to National Commercial Banks. The company is a subsidiary of Bank of America Corporation, which also falls under the same SIC classification. BofA Finance LLC was incorporated in Delaware and has its business address at 100 North Tryon Street, Charlotte, NC.
What the Filing Says
The filing, identified by accession number 0001918704-26-033358, details that the notes are linked to the least performing of the EURO STOXX 50 Index, the Russell 2000 Index, and the SPDR Gold Shares. The notes will feature a contingent coupon rate of 10.10% per annum, payable quarterly if certain conditions are met.
Impact
This offering may affect investors interested in yield notes, as well as the broader market for structured financial products. The notes are designed for investors who seek exposure to the performance of major market indices while also accepting a degree of risk associated with potential declines in value.
What's Next
The notes will be issued on October 30, 2026, following the pricing date of October 27, 2026. Further details regarding the performance of the underlying assets will be outlined in subsequent filings.
Read Next
Workers United Files to Sell $8.4 Million in Amalgamated Stock
Carvana Co. files to sell 10 million shares of stock
Platford Giles Richard to Sell 55,617 Takeda Shares
Takeda's Teresa Bitetti to Sell 46,609 Shares Amid Tax Obligations
Kiniksa Pharmaceuticals reports significant stock sale by officer
Moat Ross to Sell Over 103,000 Shares of Kiniksa Pharmaceuticals










